CD49d, the α-chain of the integrin heterodimer α4β1 (CD49d/CD29) is expressed on cell surface of ~40% of chronic lymphocytic leukemia (CLL) cases. It mediates both cell–cell and cell–matrix adhesion through binding to the vascular cell adhesion molecule-1 (VCAM-1) and fibronectin (FN), respectively. These interactions regulate CLL cell recirculation from the blood stream to tissue sites, as well as the transmission to CLL cells of signals of pro-survival and resistance to drug-induced apoptosis.1 Consistent with this functional role in CLL, a recent worldwide meta-analysis carried out on a large patient cohort, definitely demonstrated the independent prognostic relevance of CD49d in this disease
Persistent CD49d engagement in circulating CLL cells: a role for blood-borne ligands?
Zaja, F;POZZATO, GABRIELE;
2016-01-01
Abstract
CD49d, the α-chain of the integrin heterodimer α4β1 (CD49d/CD29) is expressed on cell surface of ~40% of chronic lymphocytic leukemia (CLL) cases. It mediates both cell–cell and cell–matrix adhesion through binding to the vascular cell adhesion molecule-1 (VCAM-1) and fibronectin (FN), respectively. These interactions regulate CLL cell recirculation from the blood stream to tissue sites, as well as the transmission to CLL cells of signals of pro-survival and resistance to drug-induced apoptosis.1 Consistent with this functional role in CLL, a recent worldwide meta-analysis carried out on a large patient cohort, definitely demonstrated the independent prognostic relevance of CD49d in this disease| File | Dimensione | Formato | |
|---|---|---|---|
|
leukemia CD49 2016.pdf
Accesso chiuso
Tipologia:
Documento in Versione Editoriale
Licenza:
Digital Rights Management non definito
Dimensione
349.19 kB
Formato
Adobe PDF
|
349.19 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
